Adalimumab-induced lupus pernio-like eruption in a patient with psoriasis  by Chen, Po-Hua & Tsai, Tsen-Fang
lable at ScienceDirect
DERMATOLOGICA SINICA 33 (2015) 249e250Contents lists avaiDermatologica Sinica
journal homepage: http: / /www.derm-sinica.comCORRESPONDENCEAdalimumab-induced lupus pernio-like eruption in a patient with
psoriasisDear Editor,
Psoriasis is an immune-mediated cutaneous inﬂammatory dis-
ease, and both anti-tumor necrosis factor (TNF) and Th17 are
considered to play major roles in its pathogenesis.1 Biologics,
including anti-TNF and antieinterleukin-12/interleukin-23 agents,
have been increasingly used for the treatment of psoriasis due to
their efﬁcacy and safety compared to conventional systemic agents.
However, various cutaneous adverse reactions have been reported,
especially after anti-TNF agents.2 We report a case of lupus pernio-
like eruption occurring shortly after adalimumab treatment for
psoriasis.
A 32-year-old Taiwanese man suffered from chronic plaque
psoriasis for 3 years. He was previously treated with metho-
trexate, which was discontinued due to acneiform eruptions
and intolerable gastrointestinal upset. Adalimumab 40 mg
biweekly was initiated with signiﬁcant improvement of his psori-
asis. However, asymptomatic bilateral facial erythema occurred 2
months later. The lesions progressed despite topical treatment
with tacrolimus ointment (Figure 1A). Biopsy revealed multiple
foci of well-formed noncaseating granulomas composed of aggre-
gated epithelioid histiocytes involving the dermis and subcutis
(Figure 1B and C). Cutaneous sarcoidosis was diagnosed based
on the subcutaneous involvement of granuloma, which is not
seen in granulomatous rosacea. He was otherwise healthy and
the results of laboratory investigations, including assays for anti-
nuclear, anti-dsDNA antibodies, and screening for extractable nu-
clear antigens were unremarkable. Chest X-ray and 24-hour
urinary excretion of calcium were normal. Gallium-67 whole
body scan with regional single photon emission computed to-
mography revealed symmetrically increased gallium tracer up-
take at lacriminal and salivary glands, compatible with typical
panda sign (Figure 1D). On the basis of these clinicopathological
features and image study, the rashes were diagnosed as lupus
pernio, a special form of sarcoidosis. After discontinuation of ada-
limumab and treatment with oral doxycycline 100 mg twice
daily, his facial erythema improved markedly in 4 weeks, andConﬂicts of interest: The authors declare that they have no ﬁnancial or non-ﬁnancial co
http://dx.doi.org/10.1016/j.dsi.2015.03.011
1027-8117/Copyright © 2015, Taiwanese Dermatological Association. Published by Elsevresolved completely after 2 months (Figure 1E). Ustekinumab
was initiated 6 months later due to psoriasis recurrence without
relapse of sarcoidosis.
The cutaneous side effects of anti-TNF agents have been well
established in recent years and consist of either infectious or
immune-mediated disorders.3 Inﬂammatory skin disorder such
as psoriasis, acneiform dermatitis, and rosacea have been well
documented in the literature both in rheumatology and derma-
tology ﬁelds.3,4 Anti-TNF therapy has been used to treat
steroid-resistant sarcoidosis, but paradoxically, noninfectious
cutaneous granulomatous reactions, such as cutaneous sarcoid-
osis, interstitial granulomatous dermatitis (IGD), and dissemi-
nated granuloma annulare have also been documented.3,5
Inhibition of complement cascade activation was described as
the possible mechanism of anti-TNF agents (including adalimu-
mab and inﬂiximab) in the treatment of granulomatous disor-
ders.6 However, the pathomechanism of anti-TNF agent-induced
granulomatous reaction remains unknown. Sarcoidosis is a sys-
temic granulomatous disease of unknown etiology that can affect
multiple organs. Lupus pernio is a variant of cutaneous sarcoid-
osis presenting with erythematous to violaceous nodules and
plaques located symmetrically over the nose, cheeks, ears, and
digits. The presence of lupus pernio may suggest a more aggres-
sive form of the disease.5,7
Sarcoidosis developing after TNF blockers has been considered
to be a class phenomenon that may occur after the use of drugs
sharing similar mode of action.8 However, rechallenge of TNF
blockers does not always trigger the recurrence of sarcoidosis and
etanercept-induced sarcoidosis has also been reported to resolve
after adalimumab treatment. Although sarcoidosis is a well-
recognized complication following treatment of TNF blockers, a
similar phenomenon has not been reported in Han Chinese, which
may be due to decreased prevalence of sarcoidosis among Han Chi-
nese compared to Caucasians. Although coincidence cannot be
ruled out, we propose that clinicians should bear in mind the pos-
sibility of sarcoidosis-like eruption development in Han Chinese
patient receiving TNF blockers.nﬂicts of interest related to the subject matter or materials discussed in this article.
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Figure 1 (A) Variously-sized reddish papules distributed within ill-deﬁned erythematous inﬁltrative plaques over bilateral cheeks of the patient. (B) Multiple foci of well-formed
granulomas composed of aggregate of epithelioid histiocytes and with prominent surrounded lymphocytes in the dermis and included subcutis. (C) High-powered view of subcutis
lesion: aggregation of epithelioid histiocytes within clear background and few surrounded lymphocytes, indicating a naked granuloma. (D) Symmetrically increased gallium tracer
uptake at lacrimal and salivary glands (panda sign) in gallium-67 whole body inﬂammation survey with regional single photon emission computed tomography. (E) Complete res-
olution of facial skin lesions after 2 months of discontinuation of adalimumab.
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